View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 1, 2016updated 13 Jul 2022 10:13am

Cellceutix begins Phase IIb clinical trial of Prurisol to treat psoriasis

US-based clinical stage biopharmaceutical company Cellceutix has begun its Phase IIb clinical trial of Prurisol to treat moderate-to-severe chronic plaque psoriasis.

US-based clinical stage biopharmaceutical company Cellceutix has begun its Phase IIb clinical trial of Prurisol to treat moderate-to-severe chronic plaque psoriasis.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Psoriasis is a chronic, immune-mediated skin disorder characterised by raised and inflamed skin on the elbows, knees, scalp, hands and feet, causing itching, irritation, stinging and pain.

The randomised, double-blind, parallel-group, placebo-controlled study is expected to involve approximately 189 patients and has started screening patients.

Patients will be randomised on a 3:1:3 basis to be administered with Prurisol and placebo for a duration of 12 weeks.

The study is primarily focused on determining the efficacy of Prurisol, which will be determined on the basis of Psoriasis Area and Severity Index (PASI), enabling a more direct comparison to already approved psoriasis drugs.

The secondary endpoints of the study are to find out the potential benefits of Prurisol compared to marketed therapies, both oral and biologic.

"A new oral drug that delivers substantial efficacy, expanding choices for treatment, should command considerable market value and add value for our shareholders."

Cellceutix president and chief medical officer Arthur Bertolino said: “The start of this study is a key milestone for our psoriasis programme, bringing us closer to the Phase III registration programme, and its results will further build upon the positive Phase II data reported earlier this year.

“A new oral drug that delivers substantial efficacy, expanding choices for treatment, should command considerable market value and add value for our shareholders.”

An interim analysis of a six-week data from this trial is expected to be released in the second quarter of next year.

Acting through immune modulation and PRINS reduction, Prurisol is a dermatology compound currently in mid-stage development as an oral psoriasis treatment.


Image: Psoriasis on toenails. Photo: courtesy of JVO27/Wikipedia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena